INCYTE CORP

Alpha Score of 42 reflects weak overall profile with strong momentum, weak value. Based on 2 of 4 signals — score is capped at 75 until remaining data ingests.

Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics targeting hematology, oncology, inflammation, and autoimmunity. Its portfolio features key products such as JAKAFI (ruxolitinib), approved for intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; OPZELURA, addressing atopic dermatitis and vitiligo in the dermatology segment; and MONJUVI/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma. Additional offerings include PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor, alongside NIKTIMVO, ZYNYZ, and ICLUSIG, contributing to its expanding hematology and oncology segments. Incyte Corporation also generates royalty revenues from partnered products like Jakavi and Olumiant. The company operates across the United States, Europe, Canada, and Japan, advancing a pipeline of candidates in oncology and immunology to address unmet medical needs. Founded in 1991 and headquartered in Wilmington, Delaware, Incyte Corporation plays a significant role in delivering targeted therapies for complex diseases.